Features
Subjects
Most Recent
Data Diving
By Kerry Grens | May 1, 2012
What lies untapped beneath the surface of published clinical trial analyses could rock the world of independent review.
Freezing Time
By Vern L. Schramm | May 1, 2012
Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.
Telomeres in Disease
By Rodrigo Calado and Neal Young | May 1, 2012
Telomeres have been linked to numerous diseases over the years, but how exactly short telomeres cause diseases and how medicine can prevent telomere erosion are still up for debate.
Deliberating Over Danger
April 1, 2012
The creation of H5N1 bird flu strains that are transmissible between mammals has thrown the scientific community into a heated debate about whether such research should be allowed and how it should be regulated.
Are Cancer Stem Cells Ready
for Prime Time?
By Suling Liu, Hasan Korkaya, and Max S. Wicha | April 1, 2012
A flood of new discoveries has refined our definition of cancer stem cells. Now it’s up to human clinical trials to test if they can make a difference in patients.
Best Places to Work Postdocs, 2012
By Sabrina Richards | March 29, 2012
Much has changed in the last 10 years for postdocs, who are staying in their positions longer than ever before—and coming out with more to show for it.
Vitamin D on Trial
By Amy Maxmen | March 1, 2012
Prevention trials for vitamins and supplements are notoriously difficult, but some researchers aren’t giving up on finding proof that vitamin D helps ward off disease.
Child-Proofing Drugs
By Edyta Zielinska | March 1, 2012
When children need medications, getting the dosing and method of administration right is like trying to hit a moving target with an untried weapon.
What it Takes to Develop Better Drugs for Kids
By J. Steven Leeder | March 1, 2012
Over the past 15 years, new laws and regulations in the United States and the European Union have expanded to…
Are the Kids Alright?
By Bob Grant | March 1, 2012
Two key pieces of legislation, enacted to spur drugmakers into testing pharmaceutical products in children, are up for reauthorization in the US Congress this October. Have they done their jobs?
